(Q35091558)

6 August 2017

1 reference

title

Modulation of antitumor immune responses by hematopoietic cytokines (English)

1 reference

6 August 2017

1

Edmund K Waller

1 reference

6 August 2017

Marc S Ernstoff

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

97

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

1797-1809

1 reference

Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

A fresh look at tumor immunosurveillance and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Cytokines and immune response in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza A viruses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

The risk of autoimmunity associated with tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Function and dysfunction of CD4(+) T cells in the immune response to melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Tolerance and cancer: a critical issue in tumor immunology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Immunologic dysfunction in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Immune selection in neoplasia: towards a microevolutionary model of cancer development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.11247

1 reference

7 January 2021

Targeting p53, hdm2, and CD19: vaccination and immunologic strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

T cell co-stimulation and in vivo tolerance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Autocrine and paracrine regulation by cytokines and growth factors in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Negative regulation of Janus kinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Immunotherapy of metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

In vivo activation of antigen-specific CD4 T cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Dendritic cells presenting tumor antigen.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Innovations in allogeneic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Differentiation and expansion of lentivirus vector-marked dendritic cells derived from human CD34(+) cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Cytokine enhancement of immunogenicity in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Biological concepts of prolonged neoadjuvant treatment plus GM-CSF in locally advanced tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Phase II trial of GM-CSF in advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcom

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Development of a recombinant growth factor and fusion protein: lessons from GM-CSF.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11247

7 January 2021

Identifiers

DOI

10.1002/CNCR.11247

1 reference

6 August 2017

1 reference